Eagle Pharma CFO Brian Cahill resigns effective immediately; Steven Ratoff named Interim CFO

EAGLE PHARMACEUTICALS, INC.

CFO Brian Cahill resigned March 8, 2024; separation includes cash severance of $423,340 base plus $254,004 target bonus paid over 12 months.
Director Steven Ratoff appointed Interim CFO; to receive $154,000/month for first 3 months, $77,000/month thereafter, term <12 months.
Cahill’s time-based equity awards continue outstanding for 12 months, then vest for those scheduled during that period; performance awards forfeited.
Consulting services of former CEO Scott Tarriff terminated effective Feb 29, 2024.
Board committee changes: Ratoff steps down from Audit and Compensation; Jennifer Simpson named Lead Independent Director.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Brian Cahill

Chief Financial Officer

EAGLE PHARMACEUTICALS, INC.

Effective: 2024-03-08
Successor: Steven Ratoff
Filed: March 8, 2024, 6:59 PM ET

On March 8, 2024, Brian Cahill resigned from his position as Chief Financial Officer of Eagle Pharmaceuticals, Inc. (the “Company”), effective immediately.

Appointed (interim)

Steven Ratoff

Interim Chief Financial Officer

EAGLE PHARMACEUTICALS, INC.

Effective: 2024-03-08
Filed: March 8, 2024, 6:59 PM ET

Steven Ratoff, a member of the Board and Chair of the Audit Committee of the Board (the “Audit Committee”), was appointed Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately

Role change

Jennifer Simpson

Lead Independent Director

EAGLE PHARMACEUTICALS, INC.

Effective: 2024-03-08
Filed: March 8, 2024, 6:59 PM ET

the Board appointed Dr. Simpson to serve as the Lead Independent Director of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Cahill resigned as Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On March 8, 2024, Brian Cahill resigned from his position as Chief Financial Officer of Eagle Pharmaceuticals, Inc. (the “Company”), effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven Ratoff was appointed as Interim Chief Financial Officer at EAGLE PHARMACEUTICALS, INC..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

Steven Ratoff, a member of the Board and Chair of the Audit Committee of the Board (the “Audit Committee”), was appointed Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company, effective immediately

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Simpson was appointed as Lead Independent Director at EAGLE PHARMACEUTICALS, INC..

Action: appointed
Role: Lead Independent Director

Exact text from the filing

the Board appointed Dr. Simpson to serve as the Lead Independent Director of the Board.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-24-032458

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.